CompletedNCT03061565
Long Term Effects of Erythropoietin in Patients With Moderate to Severe Traumatic Brain Injury
Studying Moderate and severe traumatic brain injury
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Australian and New Zealand Intensive Care Research Centre
- Principal Investigator
- Rinaldo BellomoANZIC-RC Monash University
- Intervention
- erythropoietin(drug)
- Enrollment
- 356 target
- Eligibility
- 15-75 years · All sexes
- Timeline
- 2017 – 2022
Study locations (1)
- Australian and New Zealand Intensive Care Research Centre, Monash University, Melbourne, Victoria, Australia
Collaborators
Monash University
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03061565 on ClinicalTrials.govOther trials for Moderate and severe traumatic brain injury
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE4NCT06866691Seizure Prevention in Traumatic Brain Injury With Levetiracetam and LacosamideWake Forest University Health Sciences
- RECRUITINGNANCT06241482Safety and Efficacy of Enhanced Recovery After Surgery in Neurocritical CareShanghai 6th People's Hospital
- RECRUITINGPHASE1, PHASE2NCT06282965Safety and Efficacy of Angiotensin (1-7) in Persons With Moderate to Severe Traumatic Brain InjuryUniversity of Arizona
- RECRUITINGPHASE1NCT05716048Combinatory Rehabilitation Used for Substantially Helping Individuals With Traumatic Brain InjuryKessler Foundation
- ACTIVE NOT RECRUITINGNANCT05636020Intervention to Change Affect Recognition and EmpathyIndiana University
See all trials for Moderate and severe traumatic brain injury →